Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
British journal of haematology
Year: 2019, Jahrgang: 184, Heft: 6, Pages: 1018-1021 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/bjh.15204 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1111/bjh.15204 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15204 
|
| Verfasserangaben: | Oliver G. Ottmann, Carsten Müller‐Tidow, Alwin Krämer, Richard F. Schlenk, Michael Lübbert, Gesine Bug, Utz Krug, Tilmann Bochtler, Florian Voss, Tillmann Taube, Dan Liu, Pilar Garin‐Chesa, Hartmut Döhner |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666609471 | ||
| 003 | DE-627 | ||
| 005 | 20230426220718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190603s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.15204 |2 doi | |
| 035 | |a (DE-627)1666609471 | ||
| 035 | |a (DE-599)KXP1666609471 | ||
| 035 | |a (OCoLC)1341225823 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ottmann, Oliver G. |e VerfasserIn |0 (DE-588)1073558401 |0 (DE-627)829169059 |0 (DE-576)435167081 |4 aut | |
| 245 | 1 | 0 | |a Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia |c Oliver G. Ottmann, Carsten Müller‐Tidow, Alwin Krämer, Richard F. Schlenk, Michael Lübbert, Gesine Bug, Utz Krug, Tilmann Bochtler, Florian Voss, Tillmann Taube, Dan Liu, Pilar Garin‐Chesa, Hartmut Döhner |
| 264 | 1 | |c 2019 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 08 June 2018 | ||
| 500 | |a Gesehen am 03.06.2019 | ||
| 650 | 4 | |a acute myeloid leukaemia (AML) | |
| 650 | 4 | |a new drug development | |
| 650 | 4 | |a new drugs for leukaemia | |
| 650 | 4 | |a oncology | |
| 650 | 4 | |a pharmacokinetics | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 700 | 1 | |a Bochtler, Tilmann |d 1975- |e VerfasserIn |0 (DE-588)128398957 |0 (DE-627)372639925 |0 (DE-576)187323909 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d Oxford [u.a.] : Wiley-Blackwell, 1955 |g 184(2019), 6, Seite 1018-1021 |h Online-Ressource |w (DE-627)269758941 |w (DE-600)1475751-5 |w (DE-576)09113997X |x 1365-2141 |7 nnas |a Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia |
| 773 | 1 | 8 | |g volume:184 |g year:2019 |g number:6 |g pages:1018-1021 |g extent:4 |a Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia |
| 856 | 4 | 0 | |u https://doi.org/10.1111/bjh.15204 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15204 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190603 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 128398957 |a Bochtler, Tilmann |m 128398957:Bochtler, Tilmann |d 910000 |d 910100 |e 910000PB128398957 |e 910100PB128398957 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1666609471 |e 3480765890 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"4 S."}],"id":{"doi":["10.1111/bjh.15204"],"eki":["1666609471"]},"note":["First published: 08 June 2018","Gesehen am 03.06.2019"],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"origin":[{"dateIssuedKey":"1955","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1955-","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]"}],"recId":"269758941","corporate":[{"display":"British Society for Haematology","role":"isb"},{"role":"isb","display":"European Hematology Association"}],"note":["Gesehen am 08.05.08"],"disp":"Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemiaBritish journal of haematology","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["269758941"],"doi":["10.1111/(ISSN)1365-2141"],"issn":["1365-2141"],"zdb":["1475751-5"]},"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"pubHistory":["1.1955 -"],"part":{"pages":"1018-1021","extent":"4","issue":"6","text":"184(2019), 6, Seite 1018-1021","year":"2019","volume":"184"},"language":["eng"],"title":[{"title_sort":"British journal of haematology","subtitle":"BJHaem : an official journal of the British Society for Haematology","title":"British journal of haematology"}]}],"recId":"1666609471","origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"family":"Ottmann","display":"Ottmann, Oliver G.","role":"aut","given":"Oliver G."},{"family":"Krämer","given":"Alwin","role":"aut","display":"Krämer, Alwin"},{"role":"aut","given":"Tilmann","display":"Bochtler, Tilmann","family":"Bochtler"}],"name":{"displayForm":["Oliver G. Ottmann, Carsten Müller‐Tidow, Alwin Krämer, Richard F. Schlenk, Michael Lübbert, Gesine Bug, Utz Krug, Tilmann Bochtler, Florian Voss, Tillmann Taube, Dan Liu, Pilar Garin‐Chesa, Hartmut Döhner"]},"title":[{"title":"Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia","title_sort":"Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia"}],"language":["eng"]} | ||
| SRT | |a OTTMANNOLIPHASEIDOSE2019 | ||